ClinicalTrials.gg
RecruitingNCT06576401Updated Sep 4, 2024

A Study To Characterize Mass Balance Of [14C] HDM1002 in Chinese Healthy Subjects

A Phase 1 interventional study of [14C] HDM1002 in Healthy Adult Subject, sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-04.

Sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (part of Huadong Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Aug 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

In this study, a single dose of [14C] radiolabelled HDM1002 will be administered orally. The main purpose of this study is to find out how much of HDM1002 and its metabolites pass from blood into urine and feces, and characterize the metabolic profile and routes of excretion of oral [14C] HDM002.

02

Conditions studied

  • Healthy Adult Subject

Keywords

  • HDM1002
  • Glucagon-Like Peptide-1 Receptor Agonists
03

In context

Lead sponsor

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. is the lead sponsor of 50 studies on the registry; 38 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male, healthy adult;
  2. Age of 18 to 45 years old (both inclusive);
  3. (BMI) between 19.0- 32.0 kg/m2 (both inclusive) and body weight no less than 50.0 kg.

Exclusion criteria

Exclusion Criteria:

  1. diseases at the time of screening;
  2. History or family history of medullary thyroid carcinoma, thyroid C-cell hyperplasia, or multiple endocrine neoplasia type 2 (MEN2), or calcitonin ≥ 35 ng/L during the screening period;
  3. History of chronic pancreatitis or acute pancreatitis within 3 months prior to screening;
  4. History of acute cholecystitis attack within 3 months prior to screening;
  5. Participant judged by investigator has dysphagia, diseases or conditions that affect gastric emptying or affect the absorption of nutrients in the gastrointestinal tract, such as bariatric surgery or other gastrectomy, irritable bowel syndrome, dyspepsia, etc.;
  6. Any of the following: habitual constipation or diarrhea, hemorrhoids or accompanied by perianal disease, irritable bowel syndrome, inflammatory bowel disease, etc;
  7. Use of any prescription medication, over-the-counter medication, Chinese herbal medicine or food supplement within 14 days or 5 half-lives (whichever is longer) prior to the screening period;
  8. Patients with any abnormal and clinically significant examinations in given comprehensive physical examination;
  9. History of drug abuse (e.g., morphine, ketamine, tetrahydrocannabinolic acid, metham phetamine, methylenedioxyamphetamine, cocaine) or positive urine drug test during the screening period;
  10. Positive for surface antigen or E antigen, virus antibody IgG (Anti-HCV IgG), antigen/antibody combination test (HIV-Ag/Ab) and Treponema pallidum antibody during the screening period.
  11. Engaged in working conditions requiring long-term exposure to radioactivity; or significant radioactive exposure ( ≥ 2 CT chest/abdomen tests, or ≥ 3 all other types of X-rays test) within 1 year prior to the trail, or participated in radio-label trails;
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    [14C] HDM1002

    A single dose of HDM1002 and \[14C\] HDM1002 administered orally.

    Drug: [14C] HDM1002

Interventions

06

What researchers measure

Primary outcomes

  1. Total recovery of HDM1002 radioactivity in urine and feces, following oral administration of [14C] HDM1002

    Total recovery of radioactivity in urine and feces, and both routes combined expressed as a percentage of the total radioactive dose administered

    Time frame: Predose up to Day 11 after administration of [14C] HDM1002

  2. Metabolite profiling/identification in plasma, urine, and feces

    Metabolic profiling/identification and determination of relative abundance of \[14C\]PF-06882961 and the metabolites of \[14C\] HDM1002 in plasma, urine, and feces.

    Time frame: Predose up to Day 11 after administration of [14C] HDM1002

  3. Plasma and whole blood AUC[0-t] of radioactivity

    PK parameter : Area under the curve from time 0 to t hour

    Time frame: Predose up to Day 11 after administration of [14C] HDM1002

  4. Plasma and whole blood AUC[0-∞] of radioactivity

    PK parameter : Area under the curve from time 0 hour to ∞

    Time frame: Predose up to Day 11 after administration of [14C] HDM1002

  5. Plasma and whole blood Cmax of radioactivity

    PK parameter : Maximum observed concentration

    Time frame: Predose up to Day 11 after administration of [14C] HDM1002

  6. Plasma and whole blood Tmax of radioactivity

    PK parameter : Time to maximum plasma concentration

    Time frame: Predose up to Day 11 after administration of [14C] HDM1002

  7. Plasma and whole blood t1/2 of radioactivity

    PK parameter: Half life

    Time frame: Predose up to Day 11 after administration of [14C] HDM1002

  8. Plasma and whole blood CL/F of radioactivity

    PK parameter : Apparent Clearance

    Time frame: Predose up to Day 11 after administration of [14C] HDM1002

  9. Plasma and whole blood Vz/F of radioactivity

    PK parameter : Apparent volume of distribution

    Time frame: Predose up to Day 11 after administration of [14C] HDM1002

  10. Percentage of plasma HDM1002 and metabolites in total plasma radioactivity

    Percentage of plasma HDM1002 AUC in total plasma radioactivity AUC

    Time frame: Predose up to Day 11 after administration of [14C] HDM1002

Secondary outcomes

  1. Plasma AUC[0-t] of HDM1002 and metabolites

    PK parameter : Area under the curve from time 0 to t hour

    Time frame: Predose up to Day 11 after administration of [14C] HDM1002

  2. Plasma AUC[0-∞] of HDM1002 and metabolites

    PK parameter : Area under the curve from time 0 hour to ∞

    Time frame: Predose up to Day 11 after administration of [14C] HDM1002

  3. Plasma Cmax of HDM1002 and metabolites

    PK parameter : Maximum observed concentration

    Time frame: Predose up to Day 11 after administration of [14C] HDM1002

  4. Plasma Tmax of HDM1002 and metabolites

    PK parameter : Time to maximum plasma concentration

    Time frame: Predose up to Day 11 after administration of [14C] HDM1002

  5. Plasma t1/2 of HDM1002 and metabolites

    PK parameter: Half life

    Time frame: Predose up to Day 11 after administration of [14C] HDM1002

  6. Plasma CL/F of HDM1002 and metabolites

    PK parameter : Apparent Clearance

    Time frame: Predose up to Day 11 after administration of [14C] HDM1002

  7. Plasma Vz/F of HDM1002 and metabolites

    PK parameter : Apparent volume of distribution

    Time frame: Predose up to Day 11 after administration of [14C] HDM1002

  8. Adverse events (AEs)

    Number of subjects reporting AEs

    Time frame: Predose up to Day 11 after administration of [14C] HDM1002

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2024 (actual). Primary completion is estimated for Oct 2024, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2024
First posted
Aug 28, 2024
StartActual
Aug 27, 2024
Primary completionEst.
Oct 2024
CompletionEst.
Dec 2024
Last update
Sep 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06576401
Responsible party
Sponsor
First posted
Aug 28, 2024
Start date
Aug 27, 2024
Primary completion
Oct 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Sep 4, 2024

Study contacts

Liyan Miao
Contact
miaolysuzhou@163.com
0512-67972858

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HDM1002

Start the discussion